The cost-effectiveness of alendronate in the prevention of osteoporotic fractures in elderly women;Bruk av alendronat ved osteoporose - Er det kostnadseffektivt?

Tidsskrift for den Norske Laegeforening

Volumn 117, Issue 18, 1997, Pages 2619-2622

  Kristiansen, Ivar Sønbø ^a   Falch, Jan A ^b   Andersen, Line ^c   Aursnes, Ivar ^d  

^a NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^b AKER UNIVERSITY HOSPITAL   (Norway)

^c ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID;

AGED; ARTICLE; COST EFFECTIVENESS ANALYSIS; FEMALE; FRACTURE; HUMAN; MAJOR CLINICAL STUDY; OSTEOPOROSIS;

EID: 0030877287     PISSN: 00292001     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO Technical Report Series 1994; 843: 1-35.
2. Dempster DW, Lindsay R. Pathogenesis of osteoporosis. Lancet 1993; 341: 797-801.
3. Lindsay R. Prevention and treatment of osteoporosis. Lancet 1993; 341: 801-5.
4. Keene GS, Parker MJ, Pryor GA. Mortality and morbidity after hip fracture. BMJ 1993; 307: 1248-50.
5. Browner WS, Pressman AR, Nevitt MC, Cummings SR. Mortality following fractures in older women. The study of osteoporotic fractures. Arch Intern Med 1996; 156: 1521-5.
6. Chesnut CH, Harris ST. Short-term effect of alendronate on bone mass and bone remodeling in postmenopausal women. Osteoporosis Int 1993; 3 (suppl 3): 17-9.
7. Adami S, Baroni MC, Broggini M, Carratelli L, Caruso I, Gnessi L et al. Treatment of postmenopausal osteoporosis with continuous daily oral alendronate in comparison with either placebo or intranasal salmon calcitonin. Osteoporosis Int 1993; 3 (suppl 3): 21-7.
8. Liberman U, Weiss SR, Broll J, Minne HW, Quan H, Bell NH et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995; 333: 1437-43.
9. Black DM, Cummings SR, Karpf DB, Cauley J, Thompson DE, Nevitt MC et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996; 348: 1535-41.
10. Weinstein MC, Stason WB. Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med 1977; 296: 716-21.
11. Drummond MF, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford: Oxford Medical Publications, 1987.
12. Kristiansen IS. Økonomiske analyser av helsetiltak: om kostnad-nytte- og kostnad-effekt-analyser som hjelpemiddel for bedre ressursbruk. Tidsskr Nor Lægeforen 1990; 110: 2377-81.
13. Wilson JNG, Jungner F. Principles and practice of screening for disease. Public Health Papers nr. 34. Geneve: WHO, 1968.
14. Nord E. Kvalitetsjusterte leveår - muligheter, begrensninger, alternativer. Tidsskr Nor Lægeforen 1992; 112: 2668-70.
15. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making 1993; 13: 322-38.
16. Jönsson B, Hedbrandt J, Johnell Ò. A computer simulation program to analyse the cost-effectiveness of fracture prevention of osteoporosis. EFI Research Paper nr. 6525. Stockholm: Stockholm School of Economics, 1993.
17. Jönsson B, Christiansen C, Johnell O, Hedbrandt J. Cost-effectiveness of fracture prevention in established osteoporosis. Osteoporosis Int 1995; 5: 136-42.
18. Andersen L, Kristiansen IS, Falch JA, Aursnes I. Cost-effectiveness of five years administration of alendronate for the prevention of osteoporotic fractures in Norwegian women. Discussion paper #11/1995. Oslo: National Institute of Public Health, 1995.
19. Gärdsell P, Johnell O, Nilsson BE, Gullberg B. Predicting various fragility fractures in women by forearm bone densitometry: a follow-up study. Calcif Tissue Int 1993; 52: 348-53.
20. Finsen V, Børset M, Rossvoll I. Mobility, survival and nursing-home requirements after hip fracture. Ann Chir Gynaecol 1995; 84: 291-4.
21. Särnbo I, Johnell O. Consequences of hip fracture: a prospective study over 1 year. Osteoporosis Int 1993; 3: 148-53.
22. Felson DT, Zhang Y, Hannan MT, Kiel DP, Wilson PWF, Anderson JJ. The effect of postmenopausal estrogen therapy on bone density in elderly women. N Engl J Med 1993; 329: 1141-6.
23. Watts NB, Miller PD, Licata AA, Jackson RD, Wasnich RD, Ross PD et al. Seven years of cyclical etidronate: continued improvement in spine BMD and progressive decline in vertebral fracture incidence. Bone 1995; 17: 597-618.
24. Normaltariff for spesialistpraksis 1994-95. Lysaker: Den norske lægeforening, 1994.
25. Prisliste for DRG 1994. Oslo: Sosial- og helsedepartementet, 1994.
26. Sintonen H, Pekurinen M. A fifteen-dimensional measure of health-related quality of life (15D) and its applications. I: Walker SR, Rosser RM, red. Quality of life assessment: key issues in the 1990s. Dordrecht: Kluwer Academic Publishers, 1996: 18595.
27. Nord E. Veiledende verditall for kostnad-nytte-analyser av helsetjenester. Tidsskr Nor Lægeforen 1996; 116: 3246-9.
28. Storvik G, Natvig B, Gåsemyr J, Aursnes I. Vurdering basert på Bayesiansk statistikk av den vitenskapelige dokumentasjon av legemidlene etidronat (Didronate) og alendronat (Fosamax) for reduksjon av antall brudd hos kvinner med osteoporose. Oslo: Matematisk institutt, Universitetet i Oslo, 1997.
29. Kristiansen IS, Eggen AE, Thelle DS. Cost-effectiveness of incremental programmes for lowering serum cholesterolconcentration: is individual intervention worthwhile? BMJ 1991; 302: 1119-22.
30. Ankjaer-Jensen A, Johnell O. Prevention of osteoporosis: cost-effectiveness of different pharmaceutical treatments. Osteoporosis Int 1996; 6: 265-75.
31. Kristiansen IS, Johnell O. Economic and quality of life aspects of osteoporosis. In: Pharmacotherapy of osteoporosis. Oslo: Statens legemiddelkontroll, 1997.
32. Olsen JA. Time preferences for health gains: an empirical investigation. Health Economics 1993; 2: 257-65.
33. Williams A. Economics of coronary artery bypass grafting. BMJ 1985; 291: 326-9.
34. Weinstein MC, Stason WB. Cost-effectiveness of intervention to prevent or treat coronary heart disease. Ann Rev Public Health 1985; 6: 41-63.
35. Kawachi I, Malcolm LA. The cost-effectiveness of treating mild-to-moderate hypertension: a reappraisal. J Hypertens 1991; 9: 199-208.
36. Thorvik E, Aursnes I, Kristiansen IS, Waaler HT. Cost-effectiveness of cholesterol-lowering drugs: a review of the evidence. Wien Klin Wochenschr 1996; 108: 234-43.
37. Cummings SR, Nevitt MC, Browner WS, Stone K, Fox KM, Ensrud KE et al. Risk factors for hip fracture in white women. N Engl J Med 1995; 332: 767-73.